A Phase 3 Study of Nivolumab in Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (ATTRACTION-2): 2-Year Update Data

Gastric Cancer- Germany

doi 10.1007/s10120-019-01034-7

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Exploratory Subgroup Analysis of Patients With Prior Trastuzumab Use in the ATTRACTION-2 Trial: A Randomized Phase III Clinical Trial Investigating the Efficacy and Safety of Nivolumab in Patients With Advanced Gastric/Gastroesophageal Junction Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

A Multi-Center Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2008English

Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: A Prospective Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2014English

A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2018English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2012English

P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

638PTwo Year Survival and Safety Update for Esophageal Squamous Cell Carcinoma Treated With Nivolumab (ATTRACTION-01/ONO-4538-07)

Annals of Oncology
MedicineOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy